These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28423587)

  • 21. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.
    Wang CC; Huang KT; Chang HC; Tseng CC; Lai CH; Lan J; Liu TT; Huang CC; Lin MC
    Thorac Cancer; 2022 Jan; 13(1):38-47. PubMed ID: 34841687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
    Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
    Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.
    Dang AH; Tran VU; Tran TT; Thi Pham HA; Le DT; Nguyen L; Nguyen NV; Thi Nguyen TH; Nguyen CV; Le HT; Thi Nguyen ML; Le VT; Nguyen PH; Vo BT; Thi Dao HT; Nguyen LT; Van Nguyen TC; Bui QN; Nguyen LH; Nguyen NH; Thi Nguyen QT; Le TX; Do TT; Dinh KT; Do HN; Phan MD; Nguyen HN; Tran LS; Giang H
    Sci Rep; 2020 Feb; 10(1):2707. PubMed ID: 32066856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
    Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
    Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
    Cronin-Fenton D; Dalvi T; Movva N; Pedersen L; Hansen H; Fryzek J; Hedgeman E; Mellemgaard A; Rasmussen TR; Shire N; Hamilton-Dutoit S; Nørgaard M
    Sci Rep; 2021 Aug; 11(1):16892. PubMed ID: 34413420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
    Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
    Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.
    Ji M; Liu Y; Li Q; Li X; Ning Z; Zhao W; Shi H; Jiang J; Wu C
    Cancer Biol Ther; 2016 Apr; 17(4):407-13. PubMed ID: 26954523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India.
    Kulshrestha R; Saxena H; Kumar R; Spalgais S; Mrigpuri P; Goel N; Menon B; Rani M; Mahor P; Bhutani I
    Monaldi Arch Chest Dis; 2023 Feb; 93(4):. PubMed ID: 36723380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.
    Yang H; Zhu J; Xiao R; Liu Y; Yu F; Cai L; Qiu M; He F
    Cancer Immunol Immunother; 2022 May; 71(5):1001-1016. PubMed ID: 34542660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.
    Hu XY; Zhang W; Hu Y; Zhang Y; Gong R; Liang JY; Liu L
    J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):313-320. PubMed ID: 27376797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.